Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

With the emergence of targeted therapies, defining the best strategy for the treatment of previously untreated CLL patients remains challenging. The aim of this phase 2 study was to compare the efficacy of an association with ibrutinib and venetoclax (IV) to the standard FCR regimen in fit patients...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.641-641
Hauptverfasser:	Michallet, Anne-Sophie, Quinquenel, Anne, Letestu, Remi, Le Garff-Tavernier, Magali, Subtil, Fabien, Elsensohn, Mad-Helenie, Aurran, Therese, Laribi, Kamel, Cymbalista, Florence, Levy, Vincent, Simon, Laurence, Roos-Weil, Damien, Leblond, Veronique, Dilhuydy, Marie-Sarah, Tomowiak, Cécile, Dartigeas, Caroline, Guieze, Romain, Tournilhac, Olivier, Ferrant, Emmanuelle, de Guibert, Sophie, Feugier, Pierre, Merabet, Fatiha, Leprêtre, Stéphane, Carassou, Philippe, Gay, Julie, Hivert, Bénédicte, Fornecker, Luc Mathieu, Dupuis, Jehan, Molina, Lysiane, Villemagne, Bruno, Cartron, Guillaume, Drenou, Bernard, Mahé, Béatrice, Benbrahim, Omar, Cahu, Xavier, Portois, Christelle, Ysebaert, Loic, Nguyen-Khac, Florence, Rouille, Valérie, Delmer, Alain
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!